

FIGURE 3
Management of Immune-Related Hypothyroidism^{4,6,10,14,21}

Background: Around 5-10% of patients receiving CLTA-4 and anti-PD-1/PD-L1 antibodies are likely to develop an endocrine adverse event of any grade. Hypothyroidism was reported in approximately 2% of patients treated with ipilimumab, and 8.3% of patients treated with PD-1 inhibitors. Time of onset for hypothyroidism ranged from 0.7 weeks to 19 months. Hypothyroidism is diagnosed if TSH level is increased with a low free T4 level. When thyroid replacement is given, dose adjustments should occur no sooner than 4-6 weeks. An endocrinologist should be consulted with the exception of grade 1 or uncomplicated grade 2 hypothyroidism.

| | MANAGEMENT | | | | |
|-----------------------------|---|--|--|--|---|
| | Description | Referral | Corticosteroids | Supportive Therapy | Immune Therapy |
| HYPO- THYROIDISM | GRADE 1 Asymptomatic FT4 normal TSH >10mUI/L. | Monitor TSH before each cycle. | Not recommended. | Intervention not indicated. | Monitor closely and continue immune therapy. |
| | GRADE 2 Moderate symptoms [§] Low FT4 and/or TSH >10mUI/L. | Monitor TSH and FT4 before each cycle. Consider consultation with endocrinologist. | Not recommended. | Initiate levothyroxine therapy at 0.5-1.5 mcg/kg if no heart disease or severe co-morbidities; otherwise, start at 12 to 25mcg daily and increase dose slowly (no sooner than every 4-6 weeks)*. | Consider holding therapy until symptoms are controlled, the patient is stable on hormone therapy, and is receiving <7.5 mg of prednisone or equivalent daily. |
| | GRADE 3 Severe symptoms [‡] Very low FT4 and TSH very high. | Monitor TSH and FT4. Hospitalization indicated. | Initiate corticosteroids at a dose of 1-2 mg/kg/day methylprednisolone IV and continue until improvement to mild severity, resolve or return to baseline. Taper over at least 1 month. Commence IV hydration if indicated. | Above plus supportive therapy for severe cardio-respiratory symptoms. | |
| | GRADE 4 Life-threatening Very low FT4 and TSH very high. | | | | Discontinue therapy. |

[§] fatigue, constipation, weight gain, loss of appetite, dry skin, eyelid edema, puffy face, hair loss

[‡]bradycardia, hypotension, pericardial effusion, depression, hypoventilation, stupor, lethargy to myxedema coma

* if patient has both adrenal insufficiency and hypothyroidism, start corticosteroid for 2-3 days before levothyroxine